Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 30
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Parazitologiia ; 40(3): 201-14, 2006.
Artículo en Ruso | MEDLINE | ID: mdl-16913293

RESUMEN

According to the traditional views mites of the family Pterygosomatidae belong to the cohort Anystina (Krantz, 1978; Kethley, 1982). Kethley (1982), however, noted similarities between these mites and representatives of the cohort Eleutherengona. In the tree diagram suggesting relationships among higher taxa Prostigmata proposed by Kethley (in Norton et al., 1993) this family derives from the eleutherengone clade. However, the characters and ranges of taxa upon which Kethley's hypothesis was based were not stated. In this paper, the external morphology of pterygosomatid mites is analyzed. The data provide strong evidence supporting a close relationship between Pterygosomatidae and the <> eleutherengone mites (Raphignathae and Heterostigmata). The setation of Pterygosomatidae is similar that of Raphignathae by the absence of trichobothria, adanal setae, and by the strongly reduced leg setation. In these mites, as in the <> eleutherengones (Raphignathae) an aedeagus is present, in females, the genital and anal openings are situated close to each other and are covered by a pair of common folds, in males these openings are fused, the leg femora are not separated onto basi- and telofemur, the naso, sejugal furrow, genital papillae, and the larval Claparede's organs are absent. Some similarities in the structure of the gnathosoma and the chelicerae with Anystina (including Parasitengona) are, probably, symplesiomorphies or convergently developed. Moreover, in pterygosomatids, the gnathosomal setation is represented by a single pair of gnathobasal setae, and the cheliceral and adoral setae, present in anystoid mites and early derivative eleutherengones, are absent. We believe, therefore, that Pterygosomatidae is a separate branch within the cohort Eleutherengona. Its exact position is, however, still unclear. Among pterygosomatid genera, mites of the genus Pimeliaphilus, which possess the maximal setation, are closest to the <> habitus. These mites are known from different parts of the world parasitizing mostly secretively living arthropods. We suggest that ancestors of the family were initially associated with arthropods and parasitism of pterygosomatids on lizards is the result of host switching from arthropods to these hosts.


Asunto(s)
Ácaros/anatomía & histología , Animales , Femenino , Lagartos/parasitología , Masculino , Ácaros/clasificación , Especificidad de la Especie
2.
J Med Entomol ; 38(3): 437-40, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11372970

RESUMEN

The ectoparasitic mite Knemidokoptes jamaicensis Turk burrows into the cornified epithelium of the legs and feet of Passeriform birds and has been reported from 12 species of North American birds. Here we establish new host and distribution records for K. jamaicensis from eight species of birds from three habitats in the Dominican Republic. These species include Hispaniolan pewee (Contopus hispaniolensis Bryant), northern mockingbird (Mimus polyglottos L.), Cape May warbler (Dendoica tigrina Gmelin), prairie warbler (Dendroica discolor Vieillot), palm warbler (Dendroica palmarum Gmelin), green-tailed warbler (Microligea palustris Cory), black-crowned palm tanager (Phaenicophilus palmarum L.), and Greater Antillean bullfinch (Loxigilla violacea L.). Rates of infestation were as great as 18.2% but varied between species and habitats. Mites were far more common in the dry desert thorn scrub than they were in higher elevation and more moist habitats, despite the fact that many of the affected species had distributions that spanned multiple habitat types. Results suggest that the abundance of scaley-leg mites is controlled by the abundance of suitable host species and by specific ecological conditions that promote transmission.


Asunto(s)
Enfermedades de las Aves/parasitología , Infestaciones por Ácaros/veterinaria , Ácaros , Animales , República Dominicana , Infestaciones por Ácaros/parasitología
3.
Curr Ther Endocrinol Metab ; 6: 305-11, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9174759

RESUMEN

PIP: In 1996, an application was submitted to the US Food and Drug Administration for the use of mifepristone (RU-486) plus the prostaglandin misoprostol in medical abortion. Over 100,000 women in more than 20 countries have received this regimen, which results in pregnancy termination in 92.7-99.0% of treated women. This article presents state-of-the-art information on medical abortion. Reviewed are its pharmacokinetics and metabolism, mechanism of action, and history of use. The article outlines a standard protocol that includes RU-486 administration at the first visit (day 1), misoprostol administration at the second visit (day 3), and post-treatment examination at the third visit (days 14-20) and suggests counseling guidelines. It discusses the contraindications and potential complications of abortifacient agents. Finally, the article compares the experience in the US and Europe of medical versus surgical abortion in terms of effectiveness, complications, and acceptability.^ieng


Asunto(s)
Abortivos Esteroideos/farmacología , Aborto Inducido , Mifepristona/farmacología , Abortivos no Esteroideos/efectos adversos , Abortivos no Esteroideos/farmacología , Abortivos Esteroideos/metabolismo , Abortivos Esteroideos/farmacocinética , Femenino , Humanos , Mifepristona/efectos adversos , Mifepristona/metabolismo , Mifepristona/farmacocinética , Embarazo , Prostaglandinas/efectos adversos , Prostaglandinas/farmacología
4.
J Med Chem ; 38(6): 994-1004, 1995 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-7699716

RESUMEN

The synthesis of a series of analogues of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[(3,4-dihydro-2-methyl-4-oxo-6- quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (ICI 198583, 1) is described in which the glutamic acid residue has been replaced by other alpha-amino acids. Most of these analogues were prepared by coupling of tert-butyl-4-(prop-2-ynylamino)benzoate (37) with 6-(bromomethyl)-3,4-dihydro-2-methyl-4-oxoquinazoline (34) followed by deprotection of the tert-butyl ester to the acid and azide-mediated coupling to the appropriate amino acid or amino acid ester. In cases where the amino acid ester was unreactive with the acid azide, a modification was used in which the quinazolinone moiety was protected as its 3-(pivaloyloxy)methyl derivative. This permitted the generation of the more reactive acid chloride of the p-aminobenzoate unit. In general these modifications result in compounds that have equivalent potency to 1 as inhibitors of isolated TS except where the amino acid lacks a lipophilic alpha-substituent. These compounds appear to require the reduced folate carrier (RFC) for transport into cells, but since they are not converted intracellularly into polyglutamated forms, they have a lower level of cytotoxicity compared to 1. The removal of the alpha-carboxylic acid has given a second set of analogues of 1 which contain simple alkyl amide, benzyl, substituted benzyl, and heterocyclic benzyl amide derivatives. These are considerably less potent than 1 as TS inhibitors but display 1-10 microM cytotoxicities due to the fact that they do not require RFC transport and can presumably readily enter cells by passive diffusion through the cell membrane. Molecular modeling and NMR studies indicated that the incorporation of, respectively, 7-methyl and 2'-fluoro substituents would favor the optimum conformation of these molecules for interaction with the TS enzyme. Accordingly, these substituents were incorporated into selected examples to give the series of analogues 47-55. These all show enhanced (approximately 10-fold) inhibition of TS compared to their unsubstituted counterparts. In the substituted benzylamides (51, 52) and heterocyclic benzyl amides (53-55) the ability to enter cells by passive diffusion results in highly potent (< 1 microM) cytotoxic agents.


Asunto(s)
Antineoplásicos/síntesis química , Antineoplásicos/farmacología , Antagonistas del Ácido Fólico/síntesis química , Antagonistas del Ácido Fólico/farmacología , Ácido Glutámico/química , Quinazolinas/síntesis química , Quinazolinas/farmacología , Timidilato Sintasa/antagonistas & inhibidores , Animales , Antineoplásicos/química , Ácido Fólico/análogos & derivados , Ácido Fólico/farmacología , Antagonistas del Ácido Fólico/química , Leucemia L1210/tratamiento farmacológico , Leucemia L1210/enzimología , Ratones , Quinazolinas/química , Relación Estructura-Actividad , Células Tumorales Cultivadas
5.
Cancer Chemother Pharmacol ; 34(3): 225-9, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-8004755

RESUMEN

AG-331 (N6[4-(N-morpholinosulfonyl)benzyl]-N6-methyl-2,6-diamino- benz[cd]indole glucuronate) is a novel lipophilic thymidylate synthase (TS) inhibitor. The properties of this compound were investigated in H35 rat hepatoma cells and in three variant cell lines resistant to antifolates by differing mechanisms. There was no evidence for any intracellular effect of AG-331 on dihydrofolate reductase (DHFR); however, the low degree of cross-resistance found for the H35FF line, which has elevated TS levels, suggested that TS may not be the sole locus of action of AG-331 in hepatoma cells. TS-directed effects of AG-331 were suggested by the pattern of its inhibition of deoxyuridine incorporation into DNA and the lesser effects of purine incorporation. In addition, H35 cells treated with 10 microM AG-331 were shown to accumulate in the S phase of the cell cycle, and this effect could be reversed by coadministration of thymidine. However, when treatments were conducted at a 5-fold higher concentration of AG-331, no S-phase block was apparent, suggesting the loss of a TS-directed effect at high inhibitor concentrations. Thymidine and folinic acid also failed to protect cells against AG-331 cytotoxicity, suggesting an alternate mode of action. Similar results were also obtained in protection experiments with a human hepatoma cell line, HEPG2, although previous results obtained in colon- and breast-cancer cell lines have suggested TS specific effects for AG-331. The possibility that biotransformation of AG-331 to other toxic species may occur in liver-derived cell lines has yet to be investigated.


Asunto(s)
Antimetabolitos Antineoplásicos/farmacología , Indoles/farmacología , Timidilato Sintasa/antagonistas & inhibidores , Animales , Neoplasias Hepáticas Experimentales/tratamiento farmacológico , Ratas , Células Tumorales Cultivadas
6.
ASAIO J ; 40(1): 56-61, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-8186493

RESUMEN

The relationship between neutrophil activation and complement activation during open heart surgery was evaluated by measuring plasma lactoferrin and C3a des Arg (C3a) in 30 adult patients undergoing coronary artery surgery. Measurements were made before induction of anesthesia, before cardiopulmonary bypass, at the end of bypass, and 10 min after protamine infusion. Changes in the measured parameters thus reflected activation during the three distinct phases of cardiac surgery: pre cardiopulmonary bypass, the bypass phase, and the heparin neutralization phase. A major rise in lactoferrin occurred in the pre bypass period, from 99 +/- 13 (mean +/- SEM) to 647 +/- 48 ng/ml (p < 0.001). During this time, C3a levels did not rise significantly (384 +/- 22 to 439 +/- 36 ng/ml). The bypass procedure resulted in a rise of both lactoferrin and C3a levels, with lactoferrin reaching 1,092 +/- 69 ng/ml and C3a increasing to 1,884 +/- 179 ng/ml after bypass (p < 0.001 for both). In individual patients, however, the changes in lactoferrin during bypass did not correlate with changes in C3a levels (r = -0.06). After protamine infusion, C3a levels reached 3,301 +/- 324 ng/ml, while the plasma lactoferrin levels declined to 522 +/- 57 ng/ml. Thus, during open heart surgery, neutrophil activation, as measured by plasma lactoferrin concentration, does not correlate with complement activation resulting from the bypass procedure or the protamine neutralization of heparin. The potential clinical relevance of the neutrophil granular release of lactoferrin is discussed.


Asunto(s)
Activación de Complemento , Complemento C3a/metabolismo , Puente de Arteria Coronaria , Lactoferrina/sangre , Neutrófilos/metabolismo , Femenino , Humanos , Periodo Intraoperatorio , Masculino , Persona de Mediana Edad , Radioinmunoensayo
7.
J Biol Chem ; 268(33): 25054-62, 1993 Nov 25.
Artículo en Inglés | MEDLINE | ID: mdl-7901220

RESUMEN

P-glycoprotein is phosphorylated in cells, and it has been suggested that phosphorylation may regulate the drug transport activity of P-glycoprotein. Domain mapping, utilizing a combination of cyanogen bromide digestion and immunoblot analysis, was used to reveal the major phosphorylation sites in murine mdr1b P-glycoprotein. After labeling of J7.V1-1 cells with [32P]Pi, or labeling membranes with [gamma-32P]ATP and either protein kinase A or protein kinase C, it was found that the majority of the label was contained within a single cyanogen bromide fragment (amino acid 627-682) that encompassed the majority of the linker region. The in vitro protein kinase C phosphorylation sites within this fragment were analyzed by a combination of fast atom bombardment mass spectrometry (FABMS) and two-dimensional phosphopeptide mapping. FABMS analysis of a protein kinase C-phosphorylated synthetic peptide, corresponding to a segment of the linker region of P-glycoprotein, identified serine 669 as the single site of phosphorylation. Comparison of two-dimensional tryptic phosphopeptide maps prepared from synthetic peptide and P-glycoprotein, both of which were phosphorylated in vitro with protein kinase C, revealed that serine 669 was also the major phosphorylation site in the intact glycoprotein. The in vitro protein kinase A phosphorylation site was identified as serine 681 by site-directed mutagenesis. Inspection of the gene organization and the deduced amino acid sequence of mdr1b P-glycoprotein revealed that the linker region, although shorter than the R domain (55 versus 241 amino acids), fits the operational definition of the R domain of cystic fibrosis conductance regulator. Like the R domain, the linker region is encoded by a single exon, is highly charged with alternating acidic and basic side chains, and contains several protein kinase A/protein kinase C consensus phosphorylation sites. Since the R domain is believed to be involved in the regulation of cystic fibrosis conductance regulator function by phosphorylation, it is possible that the linker region plays a similar regulatory role in P-glycoprotein function.


Asunto(s)
Proteínas Portadoras/metabolismo , Proteínas Quinasas Dependientes de AMP Cíclico/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteína Quinasa C/metabolismo , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP , Secuencia de Aminoácidos , Animales , Sitios de Unión , Proteínas Portadoras/química , Células Cultivadas , Resistencia a Medicamentos , Glicoproteínas de Membrana/química , Ratones , Datos de Secuencia Molecular , Fosforilación , Homología de Secuencia de Aminoácido , Vinblastina/farmacología
8.
Clin Sci (Lond) ; 84(5): 537-42, 1993 May.
Artículo en Inglés | MEDLINE | ID: mdl-8504630

RESUMEN

1. Forty-five identical twin pairs, discordant for insulin-dependent diabetes mellitus, were studied with respect to their serum lipid (high-density lipoprotein, low-density lipoprotein, total cholesterol and triacyl-glycerol) and apoprotein [apoprotein A-I, apoprotein B and lipoprotein (a)] concentrations and apoprotein (a) phenotypes. The twins were compared with an age- and sex-matched non-diabetic control group. 2. A significantly higher value was found only for high-density lipoprotein cholesterol in the diabetic twins of the female twin pairs. 3. Highly significant correlations existed between the twin pairs for all lipids and lipoproteins measured, particularly lipoprotein (a), for which identical apoprotein (a) isoforms were also found. 4. Correlations existed between the non-diabetic twins and the control subjects for high-density lipoprotein cholesterol and apoprotein A-I, probably due to the rigorous matching of control subjects. 5. The similarity between values for lipids and lipoproteins in the non-diabetic twins and control subjects suggested no effect of a genetic susceptibility to insulin-dependent diabetes mellitus. The differences in lipoproteins we describe for the identical twins discordant for insulin-dependent diabetes mellitus, in whom there was no evidence of a raised urinary albumin excretion rate, does not appear to explain the excess mortality from cardiovascular disease reported in patients with this disease.


Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Enfermedades en Gemelos , Lípidos/sangre , Adulto , Apolipoproteína A-I/análisis , Apolipoproteínas B/análisis , HDL-Colesterol/sangre , Diabetes Mellitus Tipo 1/genética , Susceptibilidad a Enfermedades , Femenino , Humanos , Lipoproteína(a)/sangre , Lipoproteínas/sangre , Masculino
9.
Am J Orthod Dentofacial Orthop ; 103(2): 163-70, 1993 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-8427221

RESUMEN

This study involved the development of a questionnaire to elicit information about current trends in orthodontic practice compared with trends of 5 years ago. The subjects addressed included the use of fixed appliances, functional appliances, extraction therapy, orthodontics and the temporomandibular joint, current diagnostic aids, and medicolegal implications of orthodontic treatment. The questionnaire was mailed to 1400 orthodontic specialists who were randomly selected from across the United States. There were 814 questionnaires returned, representing a 58.14% response rate. The major results of this survey are as follows: (1) The reported extraction rate has declined from a mean of 37.74% 5 years ago to 29.28% today. (2) TMJ concerns (or medicolegal implications thereof) have had a considerable impact in this decline, with 26.4% of orthodontists being influenced, to some extent, to extract fewer teeth because of this factor. (3) The use of functional appliances has remained somewhat static over the last 5 years, after a period of rapid growth in the 5 years previous to that. (4) The preadjusted edgewise appliance is by far the most popular fixed appliance in use today, being chosen by 72.6% of respondents. Analysis of the overall results lead to the following conclusions: (1) Fixed appliance therapy is the therapy of choice of the overwhelming majority of orthodontists. The use, benefits, and role in orthodontics of functional appliance therapy is considerably less defined. (2) Treatment modalities, notably on the use of extraction and its relationship to the health of the temporomandibular joint, should be determined by research, not by legal fears or unsubstantiated allegation.


Asunto(s)
Aparatos Ortodóncicos/estadística & datos numéricos , Ortodoncia Correctiva/estadística & datos numéricos , Ortodoncia/tendencias , Extracción Dental/estadística & datos numéricos , Aparatos Activadores/estadística & datos numéricos , Adulto , Análisis de Varianza , Distribución de Chi-Cuadrado , Medicina Defensiva , Humanos , Persona de Mediana Edad , Aparatos Ortodóncicos Funcionales/estadística & datos numéricos , Ortodoncia/legislación & jurisprudencia , Ortodoncia/estadística & datos numéricos , Ortodoncia Correctiva/efectos adversos , Ortodoncia Correctiva/métodos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Radiografía Dental/estadística & datos numéricos , Encuestas y Cuestionarios , Trastornos de la Articulación Temporomandibular/etiología , Trastornos de la Articulación Temporomandibular/terapia , Extracción Dental/efectos adversos , Estados Unidos
10.
Adv Enzyme Regul ; 33: 207-18, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-7689289

RESUMEN

gamma-Glutamyl hydrolase is a ubiquitous enzyme that has the capacity to cleave gamma-glutamyl bonds of cellular folyl- and antifolylpoly-gamma-glutamates. This study has revealed that the enzyme is secreted by primary cultures of rat hepatocytes and by H35 hepatoma cells. It was found that more than 99% of the total enzyme from H35 cells accumulated in the medium after 48 hr incubation with the serum-free medium. The cells were shown to remain intact during the secretion period since lactate dehydrogenase, dihydrofolate reductase and lysosomal hydrolases other than gamma-glutamyl hydrolase were retained within the cell. When PteGlu5 (folylGlu4) is used as a substrate the initial product is PteGlu (folate), and there is no appearance of intermediate chain length pteroyl polyglutamates. Therefore, the secreted and cellular gamma-glutamyl hydrolase from hepatoma cells appears to be an endopeptidase. Polyclonal antibodies to the poly-gamma-glutamate substrates of the enzyme were prepared and characterized. The antibodies recognize the structural differences between alpha- and gamma-glutamyl linkages but appear equally active with PteGlu5 and its analogs such as 4-NH2-10-CH3PteGlu5 and pABAGlu5. The affinity of the antibodies is related to the gamma-glutamyl structure since L-glutamic acid, folate or p-aminobenzoic acid are inactive with the antibodies. Furthermore, poly-gamma-glutamate has lower affinity for the antibodies than the poly-gamma-glutamate derivatives of PteGlu, 4-NH2-10-CH3PteGlu or pABA.


Asunto(s)
Ácido Poliglutámico/metabolismo , gamma-Glutamil Hidrolasa/metabolismo , Animales , Anticuerpos , Antígenos , Unión Competitiva , Línea Celular , Medios de Cultivo Condicionados , Humanos , Ácido Poliglutámico/inmunología , Procesamiento Proteico-Postraduccional
11.
Chest ; 102(2): 628-9, 1992 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1322814

RESUMEN

Two patients with extensive small cell lung cancer developed unilateral, spontaneous pneumothoraces while receiving chemotherapy. Both pneumothoraces wee asymptomatic, required no special procedure, and resolved with continued chemotherapy. Development of spontaneous pneumothorax during chemotherapy in patients with known small cell lung cancer may represent a response to treatment.


Asunto(s)
Carcinoma de Células Pequeñas/complicaciones , Neoplasias Pulmonares/complicaciones , Neumotórax/etiología , Anciano , Carcinoma de Células Pequeñas/diagnóstico por imagen , Carcinoma de Células Pequeñas/terapia , Terapia Combinada , Femenino , Humanos , Pulmón/diagnóstico por imagen , Neoplasias Pulmonares/diagnóstico por imagen , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Neumotórax/diagnóstico por imagen , Radiografía
12.
J Med Chem ; 35(15): 2761-8, 1992 Jul 24.
Artículo en Inglés | MEDLINE | ID: mdl-1495009

RESUMEN

Modifications to the bicyclic ring system of the potent thymidylate synthase (TS) inhibitor N-[4-[N-[(2-amino-3,4-dihydro-4-oxo-6- quinazolinyl)methyl]-N-prop-2-ynylamino]benzoyl]-L-glutamic acid (1, CB3717) have led to the synthesis of a series of quinoline antifolates bearing a variety of substituents at the C2 and C4 positions. In general the synthetic route involved the coupling of the appropriate diethyl N-[4-(prop-2-ynylamino)benzoyl]-L-glutamate with a disubstituted 6-(bromomethyl)quinoline followed by deprotection using mild alkali. The compounds were tested as inhibitors of partially purified L1210 TS. As a measure of cytotoxicity, the compounds were tested for their inhibition of the growth of L1210 cells in culture. Good enzyme inhibition and cytotoxicity were found for compounds containing chloro, amino, or methyl substituents at the C2 position with chloro or bromo substituents at C4. The effect on enzyme inhibition of varying the N10 substituent of 2h was similar to that observed in the quinazolinone-containing antifolates, indicating that the quinoline compounds may be interacting with the enzyme in a similar way to the quinazolinones. Also, the introduction of a 2'-fluoro substituent into the benzoyl ring of several of the quinoline antifolates led to an increase in both TS inhibition and the inhibition of L1210 cell growth. These data demonstrate that the N3-H of the pyrimidine ring of the quinazolinone antifolates is not required for binding to TS if appropriate substituents are placed at the C2 and C4 positions of the bicyclic ring system.


Asunto(s)
Antagonistas del Ácido Fólico/farmacología , Ácido Fólico/análogos & derivados , Quinazolinas/farmacología , Timidilato Sintasa/antagonistas & inhibidores , Animales , Supervivencia Celular/efectos de los fármacos , Ácido Fólico/química , Ácido Fólico/farmacología , Antagonistas del Ácido Fólico/química , Leucemia L1210/enzimología , Ratones , Quinazolinas/química , Relación Estructura-Actividad , Células Tumorales Cultivadas
13.
J Med Chem ; 35(12): 2321-7, 1992 Jun 12.
Artículo en Inglés | MEDLINE | ID: mdl-1613755

RESUMEN

The synthesis of a series of new C2-methyl-N10-alkylquinazoline-based thymidylate synthase (TS) inhibitors containing difluroinated p-aminobenzoate rings is described. Derivatives of the N10-propargyl and N10-methylquinazoline antifolates were prepared with 2',3'-, 2',5'-, and 2',6'-difluoro substitution. The synthesis of the 2',5'-difluoro analogues involved oxidation of the difluoronitrotoluene to 2,5-difluoro-4-nitrobenzoic acid followed by glutamation, reduction, and alkylation (propargyl bromide or MeI) to the diethyl N-(4-(alkylamino)-2,5-difluorobenzoyl)-L-glutamates. For the synthesis of the 2',3'- and 2',6'-difluoro compounds a new route was devised starting from methyl 4-((tert-butoxycarbonyl)amino)-2,6-difluorobenzoate and its 2,3-substituted counterpart. Treatment with NaH and then an alkyl halide introduced the N10-substituent. The methyl ester was hydrolyzed and the resulting acid was condensed with diethyl L-glutamate. The secondary amine was liberated using CF3CO2H and coupled with 6-(bromo-methyl)-3,4-dihydro-2-methyl-4-oxoquinazoline to yield the antifolate diesters. Final deprotection with mild alkali completed the synthesis in each case. The target compounds were tested as inhibitors of partially purified L1210 TS and also examined for their inhibition of the growth of L1210 cells in culture. Compared to their nonfluorinated parent compounds all the difluoro analogues were poorer inhibitors of TS. The greatest loss of enzyme activity was seen in the N10-propargyl analogues which contained one of the fluorine atoms ortho to the amine substituent. This loss was less apparent in the N10-methyl derivatives. Despite this lower inhibition of TS the majority of new compounds have equivalent cytotoxicity to their nonfluorinated predecessors.


Asunto(s)
Antineoplásicos/síntesis química , Antagonistas del Ácido Fólico/síntesis química , Quinazolinas/síntesis química , Timidilato Sintasa/antagonistas & inhibidores , Animales , Antineoplásicos/farmacología , Benceno/química , División Celular/efectos de los fármacos , Flúor/química , Antagonistas del Ácido Fólico/farmacología , Leucemia L1210/patología , Estructura Molecular , Quinazolinas/farmacología , Relación Estructura-Actividad
14.
Cancer Res ; 52(8): 2148-55, 1992 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-1313737

RESUMEN

Biochemical and biological studies have been carried out with 2-desamino-2-methylaminopterin (dmAMT), which inhibits tumor cell growth in culture but is only a weak inhibitor of dihydrofolate reductase (DHFR). Since it was possible that the species responsible for growth inhibition are polyglutamylated metabolites, the di-, tri-, and tetraglutamates of dmAMT were synthesized and tested as inhibitors of purified recombinant human DHFR, murine L1210 leukemia thymidylate synthase (TS), chicken liver glycinamide ribonucleotide formyltransferase (GARFT), and murine L1210 leukemia aminoimidazolecarboxamide ribonucleotide formyltransferase (AICARFT). The compounds with three and four gamma-glutamyl residues were found to bind two orders of magnitude better than dmAMT itself to DHFR, TS, and AICARFT, with 50% inhibitory concentration values in the 200 to 300 nM range against all three enzymes. In contrast, at a concentration of 10 microM, dmAMT polyglutamates had no appreciable effect on GARFT activity. These findings support the hypothesis that dmAMT requires intracellular polyglutamylation for activity and indicate that replacement of the 2-amino group by 2-methyl is as acceptable a structural modification in antifolates targeted against DHFR as it is in antifolates targeted against TS. In growth assays against methotrexate (MTX)-sensitive H35 rat hepatoma cells and MTX-resistant H35 sublines with a transport defect, dmAMT was highly cross-resistant with MTX, but not with the TS inhibitors N10-propargyl-5,8-dideazafolic acid and N-(5-[N-(3,4-dihydro-2-methyl-4-ox-oquinazolin-6-yl)-N- methylamino]thenoyl)-L-glutamic acid, implicating DHFR rather than TS as the principal target for dmAMT polyglutamates in intact cells. On the other hand, an H35 subline resistant to 2'-deoxy-5-fluorouridine by virtue of increased TS activity was highly cross-resistant to N10-propargyl-5,8-dideazafolic acid and not cross-resistant to MTX, but showed partial cross-resistance to dmAMT. Both thymidine and hypoxanthine were required to protect H35 cells treated with concentrations of dmAMT and MTX that inhibited growth by greater than 90% relative to unprotected controls. In contrast, N10-propargyl-5,8-dideazafolic acid and N-(5-[N-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-yl)-N-methylamino] thenoyl)- L-glutamic acid required only thymidine for protection. Like MTX, therefore, dmAMT appears to inhibit purine as well as pyrimidine de novo synthesis, and its effect on cell growth probably reflects the ability of dmAMT polyglutamates to not only block dihydrofolate reduction but also interfere with other steps of folate metabolism, either directly or indirectly via alteration of reduced folate pools.(ABSTRACT TRUNCATED AT 400 WORDS)


Asunto(s)
Aciltransferasas/antagonistas & inhibidores , Aminopterina/análogos & derivados , Antineoplásicos/farmacología , Carcinoma Hepatocelular/patología , Antagonistas del Ácido Fólico , Transferasas de Hidroximetilo y Formilo , Timidilato Sintasa/antagonistas & inhibidores , Aminopterina/química , Aminopterina/farmacología , Animales , Antineoplásicos/química , División Celular/efectos de los fármacos , Esquema de Medicación , Ácido Fólico/análogos & derivados , Ácido Fólico/farmacología , Leucemia L1210/tratamiento farmacológico , Masculino , Metotrexato/farmacología , Ratones , Fosforribosilaminoimidazolcarboxamida-Formiltransferasa , Fosforribosilglicinamida-Formiltransferasa , Quinazolinas/farmacología , Tiofenos/farmacología , Células Tumorales Cultivadas
15.
Cancer Res ; 52(5): 1137-43, 1992 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-1737372

RESUMEN

We describe the characterization of human lymphoblastoid cell lines with acquired resistance (greater than 20,000-fold) to a novel folate-based thymidylate synthase (TS) (EC 2.1.1.45) inhibitor, C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI198583). This acquired resistance was associated with a 64-fold amplification of the TS gene, a similar elevation in the corresponding mRNA, and an approximately 200-fold increase in both TS activity and TS protein. This amplification was maintained when the cells were grown in the absence of the selective agent, ICI198583, for 340 generations. TS isolated from one of the resistant cell lines, W1-L2:C1, displayed inhibition kinetic parameters similar to those of TS isolated from the parent W1-L2 cell line. It thus appears unlikely that resistance is due to an altered TS enzyme having a lower affinity for ICI198583. The resistant cell line, W1-L2:C1, was cross-resistant to other folate-based TS inhibitors but was as sensitive as the parent cell line, W1-L2, to 5-fluorodeoxyuridine. The W1-L2:C1 cell line was collaterally sensitive to the classical dihydrofolate reductase (EC 1.5.1.3) inhibitor methotrexate as well as to the lipophilic dihydrofolate reductase inhibitors metoprine and 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazolin e glucuronic acid salt (also called trimetrexate). When the W1-L2 and W1-L2:C1 cell lines were exposed to 1 microM ICI198583 for 24 h they accumulated the same concentration of total cellular ICI198583 polyglutamates despite the fact that the latter cell line accumulated a 300-fold greater concentration of ICI198583 monoglutamate. As polyglutamates, the tetra- and pentaglutamate forms predominated in the W1-L2 cell line, whereas the diglutamate form predominated in the W1-L2:C1 cell line, with few higher polyglutamates being detected. The lack of tri- and higher polyglutamates of ICI198583 (i.e., the more active species) in the W1-L2:C1 cell line may also contribute to the observed resistance. These findings may have important implications in light of the rapid onset of resistance to antifolates in the clinic.


Asunto(s)
Antineoplásicos/farmacología , Ácido Fólico/análogos & derivados , Linfocitos/efectos de los fármacos , Timidilato Sintasa/metabolismo , Antineoplásicos/metabolismo , Línea Celular , Resistencia a Medicamentos , Ácido Fólico/metabolismo , Ácido Fólico/farmacología , Humanos , Linfocitos/enzimología , Timidilato Sintasa/antagonistas & inhibidores , Timidilato Sintasa/genética
17.
Cancer Res ; 51(15): 3874-81, 1991 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-1713122

RESUMEN

gamma-Glutamyl hydrolase (also known as conjugase) is a ubiquitous enzyme that has the capacity to cleave folyl- and antifolylpolyglutamates. This study has revealed that the enzyme is secreted by primary cultures of rat hepatocytes and by H35 hepatoma cells. H35 cells have lower cellular levels of gamma-glutamyl hydrolase than do hepatocytes but secrete a greater proportion of gamma-glutamyl hydrolase. More than 99% of the total enzyme from H35 cells accumulated in the medium after 48 h. The cells were shown to remain intact during the secretion period since lactate dehydrogenase, dihydrofolate reductase, and lysosomal hydrolases other than gamma-glutamyl hydrolase were retained within the cell. Using the substrate 4-amino-10-methyl-pteroyldiglutamate (4-NH2-10-CH3-Pte-Glu2), the intracellular and secreted enzyme form(s) from H35 cells were found to have the following properties (a) Km values of 24.3 +/- 3.7 microM and 34.8 +/- 8.6 microM, respectively, and (b) maximal activity at pH 5 to 7 and apparent molecular weights of 120,000 by gel filtration. Both the cellular and secreted enzymes convert 4-NH2-10-CH3-PteGlu4 and pteroylpentaglutamate acid, to the corresponding monoglutamates with little or no appearance of intermediate chain length polyglutamates. This suggests that both act primarily as endopeptidases. Thus far, the cellular and secreted enzymes cannot be differentiated although the current studies do not establish this point unequivocally. Alterations in the cellular and secreted H35 cell gamma-glutamyl hydrolase levels in response to changes in culture conditions revealed that glutamine enhances activity while insulin diminishes it. Other transformed cells found to secrete this protein are Hep-G2 human hepatoma, JAR human choriocarcinoma, HeLa, and rat glioma. gamma-Glutamyl hydrolase could not be detected in medium conditioned by human MCF-7 breast cancer cells, and relatively low activities were found in the medium from CCRF-CEM or K562 leukemia cells. These studies directly establish for the first time the secretion of gamma-glutamyl hydrolase in vitro.


Asunto(s)
gamma-Glutamil Hidrolasa/metabolismo , Animales , Línea Celular Transformada , Medios de Cultivo , Espacio Extracelular/enzimología , Humanos , Líquido Intracelular/enzimología , Hígado/citología , Hígado/metabolismo , Neoplasias Experimentales/enzimología , Neoplasias Experimentales/metabolismo , Ácido Poliglutámico/metabolismo , Células Tumorales Cultivadas
18.
Am J Hematol ; 37(3): 167-72, 1991 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-1907094

RESUMEN

Serum granulocyte binding IgG, IgM, and the light chain composition of granulocyte binding immunoglobulins were measured in 58 adult subjects, including 8 normal individuals, 6 with Felty syndrome, 6 with chronic idiopathic neutropenia, 32 with B-cell chronic lymphocytic leukemia (CLL), and 6 with multiple myeloma. An abnormal kappa/lambda ratio of granulocyte binding immunoglobulins was detected in 12 of 32 patients with CLL. Neutropenia in patients with CLL did not correlate with an abnormal kappa/lambda ratio or excess granulocyte binding IgG, but did correlate with granulocyte binding IgM (P less than 0.02). Eight of the 12 patients (5 with chronic idiopathic neutropenia and 3 with Felty syndrome) with an immune neutropenia without underlying neoplastic disorder had light chain restricted granulocyte binding immunoglobulins. Of all patients' sera with light chain restriction, 76% were of lambda light chain isotype. Thus, the frequent detection of light chain restriction of granulocyte binding immunoglobulins is not a reflection of malignancy but is suggestive of the somatic mutation of immunoglobulin light chain genes.


Asunto(s)
Granulocitos/metabolismo , Cadenas Ligeras de Inmunoglobulina/análisis , Inmunoglobulinas/química , Síndrome de Felty/sangre , Granulocitos/química , Humanos , Neutropenia/sangre , Unión Proteica
19.
J Med Chem ; 34(7): 2209-18, 1991 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2066994

RESUMEN

Several C2-methylquinazoline-based antifolates have been prepared in which the C9,N10 bridge has been replaced by the reversed N9,C10 unit. This series was extensively studied by incorporating further substituents at N9 and C10 as well as by modifications to the p-aminobenzoate ring. The C2-methylquinazoline analogues 29, 30, and 31 containing the methyleneoxa, methylenethia, and thia bridge units were also synthesized. In general these isosteric replacements of the bridge unit in the parent C2-methyl-N10-propargylquinazoline antifolate 2 were much less potent as inhibitors of isolated thymidylate synthase (TS) but several were at least as potent as inhibitors of L1210 cell growth in culture. The fusion of the p-aminobenzoate ring into the bicyclic systems 75 and 76 also reduced activity against TS but again gave highly cytotoxic compounds. The cytotoxicities were largely prevented by thymidine, confirming that TS is the major locus.


Asunto(s)
Hidrocarburos Aromáticos con Puentes/síntesis química , Antagonistas del Ácido Fólico/síntesis química , Quinazolinas/síntesis química , Timidilato Sintasa/antagonistas & inhibidores , Animales , Hidrocarburos Aromáticos con Puentes/farmacología , Línea Celular , Fenómenos Químicos , Química , Antagonistas del Ácido Fólico/farmacología , Leucemia L1210/tratamiento farmacológico , Ratones , Quinazolinas/farmacología , Relación Estructura-Actividad
20.
J Med Chem ; 34(5): 1594-605, 1991 May.
Artículo en Inglés | MEDLINE | ID: mdl-2033585

RESUMEN

The synthesis is described of a series of C2-methyl-N10-alkylquinazoline-based antifolates in which the p-aminobenzoate ring is replaced by the heterocycles thiophene, thiazole, thiadiazole, pyridine, and pyrimidine. These were generally elaborated by the reaction of (bromomethyl)quinazoline 18 or its N3-[(pivaloyloxy)methyl]-protected derivative 36 with suitable heterocyclic amines although each heterocyclic system required its own particular synthetic approach. The compounds were tested as inhibitors of partially purified L1210 thymidylate synthase (TS). They were also examined for their inhibition of the growth of L1210 cells in culture. The thiophene system 7 and its related thiazole 8 gave analogues that were considerably more potent than the parent benzene series 2 as inhibitors of L1210 cell growth although in general these heterocycles were somewhat poorer inhibitors of the isolated TS enzyme. The enhanced cytotoxicities of the thiophene and thiazole analogues result, at least in part, from their efficient transport into the cells via the reduced folate carrier mechanism and very good substrate activity for folylpolyglutamate synthetase. The replacement of the C2-methyl group by C2-(fluoromethyl) and C2-(hydroxymethyl) substituents in the thiophene and thiazole series gave derivatives that were only slightly less potent inhibitors of the TS enzyme but which were considerably less cytotoxic.


Asunto(s)
Antineoplásicos/síntesis química , Quinazolinas/síntesis química , Tiofenos/síntesis química , Timidilato Sintasa/antagonistas & inhibidores , Animales , Antineoplásicos/farmacología , División Celular/efectos de los fármacos , Fenómenos Químicos , Química , Leucemia L1210/tratamiento farmacológico , Leucemia L1210/enzimología , Ratones , Quinazolinas/farmacología , Relación Estructura-Actividad , Tiofenos/farmacología , Células Tumorales Cultivadas/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA